Letter: comparison of clinical prediction rules for ruling out cirrhosis in non-alcoholic fatty liver disease (NAFLD)

Gamal Shiha^{1

2}, Nabiel Mikhail^{2

3}, Reham Soliman^{2

4}

Affiliations

¹ Department of Internal Medicine, Hepatology and Gastroenterology Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
² Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbien, Egypt.
³ Biostatistics and Cancer Epidemiology, Assuit University, Assuit, Egypt.
⁴ Department of Tropical Medicine, Faculty of Medicine, Port Said University, Port Said, Egypt.

Comment

Gamal Shiha et al. Aliment Pharmacol Ther. 2022 Sep.

. 2022 Sep;56(6):1098-1099.

doi: 10.1111/apt.17174.

Gamal Shiha^{1

2}, Nabiel Mikhail^{2

3}, Reham Soliman^{2

4}

¹ Department of Internal Medicine, Hepatology and Gastroenterology Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
² Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbien, Egypt.
³ Biostatistics and Cancer Epidemiology, Assuit University, Assuit, Egypt.
⁴ Department of Tropical Medicine, Faculty of Medicine, Port Said University, Port Said, Egypt.

No abstract available

Comment on

Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).
Brandman D, Boyle M, McPherson S, Van Natta ML, Sanyal AJ, Kowdley K, Neuschwander-Tetri B, Chalasani N, Abdelmalek MF, Terrault NA, McCullough A, Bettencourt R, Caussy C, Kleiner DE, Behling C, Tonascia J, Anstee QM, Loomba R; Members of the Nonalcoholic Steatohepatitis Clinical Research Network. Brandman D, et al. Aliment Pharmacol Ther. 2022 Jun;55(11):1441-1451. doi: 10.1111/apt.16874. Epub 2022 Mar 17. Aliment Pharmacol Ther. 2022. PMID: 35302256 Free PMC article.

1. Brandman D, Boyle M, McPherson S, van Natta ML, Sanyal AJ, Kowdley K, et al. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD). Aliment Pharmacol Ther. 2022;55:1441-1451.
1. Shiha G, Soliman R, Mikhail NNH, Alswat K, Abdo A, Sanai F, et al. Development and multicenter validation of FIB-6: a novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C. Hepatol Res. 2022;52:165-75.
1. Shiha G, Soliman R, Mikhail NNH, Alswat K, Abdo A, Sanai F, et al. Multicenter external validation of FIB-6: a novel, machine learning, simple bedside score to rule out severe liver fibrosis and cirrhosis in patients with MAFLD. J Hepatol. 2022;77(S1):S479-80.
1. Boyko EJ. Ruling out or rulin in disease with the most sensitive or specific diagnostic test: short cut or wrong turn? Med Decis Making. 1994;14:763-70.
1. Lee WC. Selecting diagnostic tests for ruling out or ruling in disease: the use of the Kullback-Leibler distance. Int J Epidemiol. 1999;28(3):521.